The sho retroviral regime administration in the peripaum period decreases the risk of veical transmission by :
**Core Concept**
The question is testing the understanding of antiretroviral therapy (ART) in the prevention of mother-to-child transmission (PMTCT) of HIV. The underlying pharmacological principle is the use of combination antiretroviral therapy to suppress maternal HIV viral load, thereby reducing the risk of vertical transmission.
**Why the Correct Answer is Right**
The combination antiretroviral therapy (cART) regimen administered to the mother during pregnancy, labor, and postpartum period significantly decreases the risk of mother-to-child transmission. This is because cART suppresses the maternal HIV viral load, reducing the risk of transmission through breast milk and during delivery. The most commonly used cART regimens include zidovudine (AZT) + lamivudine (3TC) + lopinavir/ritonavir (LPV/r).
**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect as it does not specify the antiretroviral regimen used. While antiretroviral therapy is essential in PMTCT, the specific regimen is crucial in determining its effectiveness.
* **Option B:** This option is incorrect as it does not provide a clear antiretroviral regimen. The use of antiretroviral therapy is critical, but the specific combination and duration are essential in reducing the risk of vertical transmission.
* **Option D:** This option is incorrect as it does not specify the antiretroviral regimen used. While antiretroviral therapy is essential in PMTCT, the specific regimen is crucial in determining its effectiveness.
**Clinical Pearl / High-Yield Fact**
A memorable point to remember is that the World Health Organization (WHO) recommends a combination of antiretroviral drugs, including zidovudine (AZT) + lamivudine (3TC) + lopinavir/ritonavir (LPV/r), for the prevention of mother-to-child transmission of HIV. This regimen has been shown to significantly reduce the risk of vertical transmission.
**Correct Answer:** C. Zidovudine (AZT) + lamivudine (3TC) + lopinavir/ritonavir (LPV/r).